Most TSC caregivers plan to continue Epidiolex due to benefits like fewer seizures and improved cognition. New data at AES 2024 underscores Epidiolex's positive impact on TSC patients' health and well ...
The Company plans to discontinue further clinical development of ganaxolone in TSC. Marinus Pharmaceuticals announced that its phase 3 trial of ganaxolone did not meet the primary end point for the ...
Please provide your email address to receive an email when new articles are posted on . Survey responses reflected positive language and communication outcomes after cannabidiol use. Further ...
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...
The association between the treatment-induced hypertension (Htn) and response to neoadjuvant sunitinib in renal cell carcinoma (RCC). This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting ...
Biocon’s arm Biocon Pharma has received approval from the US health regulator for its generic version of everolimus tablets for oral suspension used in the treatment of tuberous sclerosis complex, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results